Zentalis Pharmaceuticals, Inc. Stock Price, News & Analysis

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has appointed Iris Roth, PhD, as Chief Operating Officer, enhancing its leadership team with her extensive oncology experience. Dr. Roth, formerly at GlaxoSmithKline, has successfully developed various cancer therapies and will aid Zentalis in advancing its clinical strategy. CEO Dr. Kimberly Blackwell expressed confidence in Dr. Roth's capabilities to foster effective drug development. Zentalis aims to release updated program timelines and potential registration paths soon, focusing on its promising pipeline that includes azenosertib and ZN-d5.

Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company, announced the grant of non-qualified stock options to a new employee on February 1, 2023. A total of 12,500 options were issued under the 2022 Employment Inducement Incentive Award Plan. The options have an exercise price of $23.65 per share, equal to the closing stock price on the grant date. They are set to vest over four years, with 25% vesting after the first year and the remaining 75% in equal monthly installments. This plan aims to attract new talent as specified by Nasdaq Listing Rule 5635(c)(4).

Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company, announced that CEO Kimberly Blackwell will participate in two significant investor conferences. The first event is the Guggenheim Healthcare Talks | Oncology Day, scheduled for February 8, 2023, at 9:00 a.m. ET in New York City. The second event is the SVB Securities Global Biopharma Conference, taking place virtually on February 14, 2023, at 3:00 p.m. ET. Webcasts of these presentations will be available on Zentalis' website, along with archived versions post-event. Zentalis focuses on developing small molecule therapeutics for cancer treatment.

Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on oncology treatments, announced the grant of 204,850 non-qualified stock options to seven new employees on December 1, 2022. This grant was made under the 2022 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4). The exercise price of the options is set at $21.09 per share, aligning with the closing price on the grant date. These options have a 10-year term and will vest over four years, contingent on continued employment.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced Q3 2022 financial results, highlighting a robust cash position of $422 million, sufficient to fund operations into 2025. The company is advancing its promising Wee1 inhibitor, ZN-c3, with ongoing studies, including monotherapy and combination therapies. A biomarker-driven trial focusing on Cyclin E driven high-grade serous ovarian cancer has been initiated, while collaborations with Pfizer and GSK aim to enhance clinical development. R&D expenses decreased to $42.2 million, while general and administrative expenses rose to $12 million due to stock-based compensations.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its CEO, Kimberly Blackwell, will engage in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 1:15 p.m. ET. This event highlights Zentalis's ongoing commitment to developing small molecule therapeutics targeting cancer pathways. A webcast will be available via the company's website, offering insights into their innovative oncology pipeline, which includes notable candidates like ZN-c3 and ZN-d5.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced on November 1, 2022, the grant of non-qualified stock options for 350,025 shares to four newly hired employees. This grant is part of their 2022 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $25.60 per share, equal to the stock's closing price on the grant date, and will vest over four years. Zentalis focuses on developing small molecule cancer therapeutics, with various oncology candidates in their pipeline.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced a collaboration with Pfizer to initiate a Phase 1/2 dose escalation study of ZN-c3, a selective Wee1 inhibitor, in treating BRAF V600E-mutated colorectal cancer. This study aims to assess the combination of ZN-c3 with encorafenib and cetuximab, part of the BEACON regimen. With 21% of metastatic colorectal cancer patients harboring BRAF mutations, this collaboration addresses a significant unmet medical need. Patient enrollment is anticipated to start in Q1 2023, offering hope for improved treatment options in this aggressive cancer type.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) has appointed Dr. Mark Lackner as Chief Translational Officer and Head of Biomarker Strategy. Dr. Lackner, a seasoned expert in oncology and biomarker development, brings over 20 years of experience from IDEAYA Biosciences and Genentech. This strategic hire aims to enhance Zentalis' clinical strategy and biomarker capabilities, particularly for the ongoing ZN-c3 biomarker trial. CEO Dr. Kimberly Blackwell emphasized that strengthening the executive team is crucial for advancing the company’s oncology pipeline, which includes promising candidates such as ZN-c3, ZN-d5, and ZN-c5.